-+ 0.00%
-+ 0.00%
-+ 0.00%

Sweden's Orexo Finalizes Divestment of Zubsolv US Rights

MT Newswires·01/01/2026 04:29:32
Listen to the news
04:29 AM EST, 01/01/2026 (MT Newswires) -- Orexo (ORX.ST) said Wednesday it completed the sale of the full US rights to its opioid use disorder drug Zubsolv to Dexcel Pharma USA, as part of the former's plan to focus on its AmorphOX drug delivery platform and other key projects. The Swedish pharmaceutical company received an upfront payment of $91 million plus the inventory value of $3.8 million. It is also eligible to receive a contingent payment of $16.8 million based on net sales for 2026 and 2027. The company intends to use the proceeds to redeem its outstanding corporate bond.